A detailed history of Meitav Dash Investments LTD transactions in Gamida Cell Ltd. stock. As of the latest transaction made, Meitav Dash Investments LTD holds 3,237,537 shares of GMDA stock, worth $97,126. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,237,537
Previous 3,655,158 11.43%
Holding current value
$97,126
Previous $1.5 Million 91.39%
% of portfolio
0.0%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$0.04 - $0.46 $16,704 - $192,105
-417,621 Reduced 11.43%
3,237,537 $129,000
Q3 2022

Oct 31, 2022

BUY
$1.53 - $3.39 $4.94 Million - $10.9 Million
3,225,806 Added 751.32%
3,655,158 $6.29 Million
Q3 2021

Nov 03, 2021

BUY
$3.85 - $6.44 $589,296 - $985,732
153,064 Added 55.4%
429,352 $1.68 Million
Q1 2021

May 06, 2021

BUY
$7.8 - $12.43 $2.06 Million - $3.28 Million
263,524 Added 2064.59%
276,288 $2.24 Million
Q4 2020

Feb 02, 2021

SELL
$4.07 - $11.0 $567,349 - $1.53 Million
-139,398 Reduced 91.61%
12,764 $106,000
Q3 2020

Nov 05, 2020

SELL
$3.93 - $4.59 $265,491 - $310,077
-67,555 Reduced 30.75%
152,162 $631,000
Q2 2020

Aug 10, 2020

BUY
$2.79 - $6.5 $613,010 - $1.43 Million
219,717 New
219,717 $1 Million
Q1 2020

May 11, 2020

SELL
$2.9 - $4.76 $648,779 - $1.06 Million
-223,717 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$4.01 - $5.25 $5,417 - $7,092
-1,351 Reduced 0.6%
223,717 $962,000
Q3 2019

Nov 14, 2019

BUY
$3.0 - $5.09 $15,000 - $25,450
5,000 Added 2.27%
225,068 $1.04 Million
Q2 2019

Aug 14, 2019

SELL
$4.98 - $11.32 $24,476 - $55,637
-4,915 Reduced 2.18%
220,068 $1.12 Million
Q1 2019

May 13, 2019

SELL
$9.8 - $14.38 $166 - $244
-17 Reduced 0.01%
224,983 $2.54 Million
Q4 2018

Feb 13, 2019

BUY
$8.44 - $15.41 $1.9 Million - $3.47 Million
225,000 New
225,000 $2.24 Million

Others Institutions Holding GMDA

About Gamida Cell Ltd.


  • Ticker GMDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,319,600
  • Market Cap $2.29M
  • Description
  • Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...
More about GMDA
Track This Portfolio

Track Meitav Dash Investments LTD Portfolio

Follow Meitav Dash Investments LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meitav Dash Investments LTD, based on Form 13F filings with the SEC.

News

Stay updated on Meitav Dash Investments LTD with notifications on news.